Presseaussendungen zu "Bachner"
603 AussendungenSaxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment …
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention.
Nicht mehr das Billigste vom Billigsten: Medizinprodukte-Branche fordert neue Beschaffungskriterien
Wien, 28. September 2020 – Die Corona-Pandemie hat die Medizinprodukte-Branche schlagartig in den Fokus der politischen Diskussion gerückt.
Das österreichische Gesundheitswesen – Das Forum Spital 2019 nennt das Sorgenkind beim Namen
Das imh Forum Spital 2019 in Mauerbach bei Wien thematisierte Gesundheitsreformen, Kassenzusammenlegungen, Finanzierungsfragen und Patiententourismus zwischen Fachkräftemangel im Gesundheitswesen und der …
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with …
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza® (liraglutide 1.8 mg) …
Konzertveranstaltungen in Niederösterreich
Vom Max Brand Ensemble bis zur Big Band Pfaffstätten
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg).
Neuer Vertriebsleiter bei Traktionssysteme Austria
Führungswechsel im TSA-Vertrieb ab 2019
„Gospel & More“ am Samstag im Bezirksmuseum 23
„Gospel & More – das ist Gospel, Soul, Funk und Gänsehaut“, erzählt der Ensemble-Leiter, Georg Weilguny.
„Unterwegs in Österreich“ ab 5. November aus Niederösterreich
Ab Montag, dem 5. November 2018, ist das mobile Sendestudio des ORF wieder in Niederösterreich unterwegs.
Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin
Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg
m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis
Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial
Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the …
